Biogen to Present 76-Week EMPAVELI Kidney Data at ASN
The data will show sustained proteinuria reduction and eGFR stabilization in C3G and primary IC-MPGN. Biogen will also share investigational felzartamab updates across kidney diseases.
The data will show sustained proteinuria reduction and eGFR stabilization in C3G and primary IC-MPGN. Biogen will also share investigational felzartamab updates across kidney diseases.